Metabolic syndrome (MetS) is a cluster of interrelated and heritable metabolic traits, which collectively impart unsurpassed risk for atherosclerotic cardiovascular disease and type 2 diabetes. Considerable work has been done to understand the underlying disease mechanisms by elucidating its genetic cause.
INTRODUCTION
Metabolic syndrome (MetS) is a cluster of metabolic traits that confer high risk for cardiovascular disease (CVD) and diabetes. Although this entity has been known for more than 6 decades [1] , its significance has only been recently realized as a public health threat with a prevalence that is soaring across all age groups [2] .
Patients with MetS have an estimated relative risk (RR) of 2.35 (2.02-2.73) for CVD [3] . Their RR for CVD mortality after adjusting for diabetes and conventional risk factors is estimated between 1.39 (1.03-1.86) [4] and 1.54 (1.32-1.79) [5] . The RR for death appears to be independent of body weight and can be as high as 4 .05 (2.38-6.89 ) in normal weight patients with MetS compared with those without MetS [4] . Even among individuals with angiographically significant coronary artery disease (CAD), the hazard ratio for cardiovascular events is much greater in those with MetS compared with those without [6] .
MetS remains a heterogeneous disorder with multiple components encompassing truncal obesity, atherogenic dyslipidemia, hypertension, glucose intolerance, a proinflammatory state, and a prothrombotic state that commonly cluster together. The spectrum of traits in a patient at the time of diagnosis may vary considerably even in affected members of the same family. This heterogeneity creates a challenge for genetic studies that hinge on a well-defined clinical phenotype for success. Attempts have been made by national and international organizations to establish a universal definition for this syndrome. The National Cholesterol Education Programme Adult Treatment Panel III criteria are widely used and require the presence of any three out of five metabolic traits for the diagnosis. These include hypertension (>130/85 mmHg), abdominal obesity (a waist circumference of !102 cm in men, !88 cm in women, !90 cm in Asian-American men, and !80 cm in Asian-American women), elevated triglycerides (triglyceride !150 mg/dl), reduced plasma HDL cholesterol (HDL <40 mg/dl in men and <50 mg/dl in women), and impaired glucose tolerance (>100 mg/dl) [7, 8] .
Recently, the CardioMetabolic Health Alliance think tank further categorized the syndrome into subtypes and stages. The subtypes include lipid dominant, adiposity dominant, vascular dominant, insulin-resistance dominant, and 'other subtype' that contains patients with hyperuricemia, chronic kidney disease or hormonal dysfunction. This effort was made to improve the characterization of the phenotype and prognostication of end-organ consequences [9 & ].
GENETIC CAUSES OF METABOLIC SYNDROME
Family and twin studies have provided the initial evidence for the heritability and co-occurrence of the metabolic traits. Heritability estimates for each of the MetS traits exceed 50%.
Genetic studies have successfully identified a number of mutations for individual traits. In this regard, progress in understanding the genetics of obesity, which plays a central role in MetS, has been substantial.
Monogenic disorders of obesity
Total body fat is determined by calories from food intake and energy expenditure, which are both influenced by genetic factors. Rare recessive mutations in the genes encoding leptin and its receptor have been associated with obesity and insulin resistance. Leptin is secreted from adipose tissue and provides an important feedback signal between the peripheral fat deposit and the hypothalamic pro-opiomelanocortin (POMC) neurons in the arcuate and paraventricular nuclei. Posttranslational processing of POMC generates melanocortin peptides a, b, and gMSH, which stimulate the melanocortin receptors 3 and 4 (MC4R and MC3R) to generate an anorectic response and reduce the fat deposit [10] . In addition, leptin inhibits the orexigenic pathway via inhibiting the agouti-related peptide and neuropeptide Y (NPY) neurons in the arcuate nucleus [11] . Mutations in MCR3, MC4R, and POMC genes have been associated with monogenic forms of obesity. Moreover, MC4R mutations account for about 6% of monogenic obesity cases in children [12] .
GENETIC APPROACHES FOR DISCOVERY OF METABOLIC SYNDROME GENES
In the following section, we will briefly explain the different approaches and their results.
Candidate gene approach
Mutation burden analysis of candidate genes is among the first methods used for discovering MetS genes. Given its biased nature, most genetic associations failed to be replicated or be identified through genome-wide association studies (GWAS). Such examples include polymorphisms in or near genes encoding SLC6A14, GAD2, and ENPP1.
Furthermore, the majority of the identified disease genes underlie only one metabolic trait. Few exceptions include variations in ADIPOQ associated with diabetes, hypertension, and dyslipidemia. Other examples include variations in NR3C1, FOXC2, SREBP1, and GNB3 genes.
Genome-wide linkage analysis
Genome-wide linkage analysis has been widely used to map disease genes for MetS. Several loci have been reported in white Americans (1p34.1, 1q41, 2p22.3, 3q27, 7q31.3, 9p13.1, 9q21.1, 10p11.2, 17p12, and 19q13.4) [13] and in Hispanics (6q and 1q23-q31) [14] . No specific gene has been identified for these loci.
Genome-wide association studies
GWAS examine the genome for common polymorphisms associated with the disease and are
KEY POINTS
MetS is a combination of heritable cardio-metabolic abnormalities that tend to cluster together and significantly increase the risk of cardiovascular events.
Only a few genes with large effects have been discovered that can explain the association of diverse traits in this syndrome.
Study of homogenous populations at the extreme ends of quantitative distribution is necessary to identify variants that underlie the association of the diverse metabolic traits of this syndrome. Elucidating the genetics of MetS can lead to pharmacotherapies that improve all the metabolic profiles in patients with this syndrome.
particularly suitable for complex traits. This unbiased approach takes advantage of linkage disequilibrium between a disease allele and nearby polymorphisms. These studies have been powered by the discovery of a massive number of polymorphisms in the human genome. Nonetheless, they also suffer from several limitations. First, uncovered genetic variants are not necessarily causative. Another setback is the requirement of a minimum allele frequency, often set at 5% in the study population. This means that the associated mutation should be ancient enough to be widespread in the study population. However, genetic variants that withstand the pressure of time often impart small effects on the trait. Moreover, these studies fall victim of multiple testing corrections that are necessary given the large number of variants used in each assay. The threshold for a 'genome-wide significance' is set at P < 5 Â 10 À8 . Nonetheless, a number of variants have been identified by GWAS that have provided insight into disease pathogenesis (Tables 1-5 ).
The BMI associated loci are over 100 ( Table 1 ). The largest GWAS meta-analysis study to date included about 340 000 individuals mainly of European descent. The analysis attributed 2.7% of BMI variation to the 97 identified loci [15 && ]. Each SNP contributed roughly a 0.1 unit increase in BMI or 0.3 kg of weight to a 1.7-m tall individual. In other words, a 29-kg weight increase is expected in an individual who harbors all the 97 at-risk variants. Interestingly, secondary analysis showed that 6.6 AE 1% of additional BMI variation could be explained by 2,346 SNPs that were associated with obesity but with a P < 5 Â 10 -3 , well below the threshold for GWAS significance. Further directionality analysis estimated that about 1000 of these SNPs represent true BMI associations. This is in comparison to the 21.6 AE 2.2% of BMI variance explained by the 1.4 million SNPs in HapMap3.
Of note, some of the obesity-associated loci showed the evidence for association with other traits of MetS based on directionality analysis. For instance, fat mass and obesity (FTO) and TMEM18 were associated with higher triglycerides, lower HDL, increased fasting insulin, increased blood pressure (BP), and CAD. HIP1, MC4R and PRKD1 were associated with higher triglyceride, lower HDL, increased fasting insulin, and CAD. FOXO3 was associated with higher triglyceride, lower HDL, increased BP, and CAD. Finally, data-driven expression-prioritized integration of complex traits analysis showed that of the 31 tissue types enriched with the obesity-associated genes, 27 were in the central nervous system and in dynamic pathways related to synaptic plasticity and glutamate signaling, which confirms the role of neurohormonal regulation and behavior in the pathogenesis of obesity [15 && ]. One of the strong and reproducible GWAS BMIassociated signals is in the FTO gene, which encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Latest follow-up mechanistic studies showed that the pathogenic alleles repress mitochondrial thermogenesis in adipocyte precursor cells and shift their differentiation from beige (energy dissipating cells) to white (energy storing) adipocytes [16 && ]. The ARID5B-IRX3-IRX5 pathway mediates this process.
Another recent GWAS included about 224 500 individuals mainly of European descent in a study of the adipose tissue distribution as measured by the BMI-adjusted waist-to-hip ratio (WHR) [17 && ]. Out of the 49 loci identified, 20 had significant sexual dimorphism and the majority had stronger effects in women. It is worth mentioning the loci that were significantly associated with multiple MetS traits. The GRB14-COBLL1 locus was associated with increased triglyceride, decreased HDL, increased fasting insulin, T2DM, and increased LDL. The MAP3K1, VEGFA and CCDC92 loci were associated with increased triglyceride and decreased HDL. The CCDC92 locus was associated with decreased BMI-adjusted-adiponectin (BAA) levels. The PPARG locus was associated with increased triglyceride and LDL. CMIP was associated with decreased HDL and BAA [17 && ].
In a meta-analysis of GWAS for dyslipidemias in over 188 000 people, 69 microRNAs were identified in genomic regions in proximity to identified SNPs. Further analysis for predicted miRNA targets identified four miRNAs with links to cardiometabolic traits; miR-128-1, miR-148a, miR-130b, and miR-301b. In-vitro and in-vivo studies showed that the latter two miRNAs influence lipid trafficking via modulating the expression of LDL receptor and ATP-binding cassette A1 cholesterol transporter (ABCA1) [18] . The study, however, did not examine the allele-specific effects of the associated SNPs on miRNAs' expression and function. Nonetheless, the findings are quite intriguing and prompt further studies to examine the association of miRNAs with metabolic traits.
In an interesting application of genetic risk scores using 19 variants associated with insulin resistance from prior GWAS studies, patients with more than 17 at-risk alleles were at significantly increased risk for T2DM, CAD, and HTN compared with those with less than nine at-risk alleles. Analysis of genetic risk scores revealed that 11 variants out of the 19 were associated with a metabolic profile consistent with MetS; higher triglyceride, lower HDL, greater hepatic steatosis, and lower adiponectin. Moreover, these variants were associated with lower BMI and increased visceral-tosubcutaneous adipose tissue ratio, which is consistent with a subtle form of lipodystrophy [19] .
Finally, some of the BMI-associated loci negatively correlate with other elements of the MetS. For instance, HHIP is associated with lower risk of T2DM and with increased levels of HDL. Similarly, IRS1 is associated with lower levels of triglyceride, higher levels of HDL, lower fasting insulin levels, and decreased CAD risk; all opposite to what would be expected with MetS [15 && ]. These findings echo prior observations that obesity does not necessarily cause metabolic abnormalities, as one-third of obese individuals have normal metabolic profile and harbor no CVD risk [20] . On the contrary, up to 45% of normal weight individuals harbor other metabolic abnormalities placing them at higher risk for CVD and T2DM [21] .
MONOGENIC CAUSES OF METABOLIC SYNDROME
Studying monogenic forms of MetS and its forme fruste partial lipodystrophies has resulted in identification of factors that underlie the association of diverse metabolic traits.
Hereditary lipodystrophies
Hereditary lipodystrophies are characterized by metabolic traits similar to MetS, except for major differences in the amount and distribution of adipose tissue and decreased leptin levels. These rare disorders include early onset congenital generalized lipodystrophy (CGL) and progeroid syndrome as well as adult onset familial partial lipodystrophies (FPLD) and mandibuloacral dysplasia. CGL has been associated with mutations in AGPAT2, BSCL2, CAV1, PTRF, and PPARG, which are mainly involved in lipid droplet formation and the biosynthesis of triglycerides and phospholipids [22] .
FPLD is the closest disorder to MetS. To date, mutations in nine different genes have been associated with FPLD. The autosomal dominant form of FPLD results from mutations in LMNA, PPARG, AKT2, and PLIN1. The autosomal recessive form involves mutations in CIDEC, LIPE, WRN, PCYT1A, and ZMPSTE24 genes [23] [24] [25] .
Wnt and low-density lipoprotein receptorrelated protein 6
MetS has been associated with mutations in the highly conserved Wnt-LDL receptor-related protein 6 (LRP6) pathway that plays a pivotal role in embryonic development and nutrient sensing. 
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The canonical Wnt pathway is activated via Frizzled family receptors and LRP5/6 coreceptors. Both canonical and noncanonical pathways inhibit mesenchymal stem cell differentiation into adipocytes via repressing PPARG [26, 27] . Several other lines of evidence indicate the importance of Wnt signaling in regulating body weight and food intake as it is expressed in the hypothalamus. Moreover, Wnt ligands and their LRP6 coreceptor are downregulated in NPY neurons in the arcuate nucleus of leptin-deficient mice [28] . LRP6 mutations such as R611C, R473Q, R360H, and N433S are associated with autosomal-dominant MetS and early onset CAD [29] . Some of these mutations reduce the canonical Wnt function by up to 40% [29] . The role of LRP6 in regulation of plasma lipids was investigated, as it is a member of the LDLR family. Studies of skin fibroblasts in LRP6 R611C mutation carriers showed reduced LDL uptake attributed to interference with LDLR internalization and clathrin-mediated LDL uptake [30] . Mouse studies implicated LRP6 in regulating LDL synthesis, de-novo lipogenesis, and VLDL secretion [31] . Finally, mice with LRP6 R611C mutation develop CAD caused by excessive proliferation of undifferentiated vascular smooth muscle cells. This is triggered by excess activity of growth factors because of the lack of TCF7L2 inhibition of Sp-1 [32] . This variant of CAD phenocopies an entity known as plaque erosion and is linked to increased activity of noncanonical Wnt signaling. Mutations in LRP6 have also been associated with nonalcoholic steatohepatitis. Studies of mouse models have 
9q CHCHD2P9 a Chromosome number. b Nearest genes to loci identified in association with insulin resistance. linked activation of noncanonical Wnt and downstream TGF pathway to liver fibrosis and inflammation. Individuals with LRP6 mutations have reduced insulin receptor expression and are insulin resistant [33] . LRP6 transcriptional regulation of insulin receptor is important for adipogenic transformation of 3T3L1 cells [34] and for preferential glucose uptake in a drosophila model of insulin resistance [35] . Reduced insulin receptor expression can be rescued by either TCF7L2 overexpression or high doses of Wnt3a (Fig. 1 ). Insulin resistance in LRP6 R611C mutation carriers is also accounted for by activation of mTORC1 pathway and serine phosphorylation of IRS1 at multiple residues.
Dyrk1B a novel gene for metabolic syndrome
We recently discovered a gain of function mutation in Dyrk1B that results in autosomal-dominant MetS with early onset CAD. Early mechanistic studies of the R102C mutation suggested increased adipocyte differentiation of precursor cells and increased transcription of glucose-6-phosphatase, the ratelimiting enzyme of gluconeogenesis [36 && ]. Dual specificity tyrosine-regulated kinase (Dyrk) family has been implicated in nutrient sensing. Dryk kinases regulate GSK3B's phosphorylation of NFAT and FOXO1 transcription factors, thereby influencing pancreatic function, skeletal muscle development, glucose, and insulin homeostasis [37] .
Dyrk1B is positively regulated at the transcriptional level by Rho GTPase-Rac 1, and negatively regulated by RAS-MEK-ERK. Interestingly, loss of function mutations in the latter inhibitory pathway is linked to obesity and insulin resistance in humans [38] . Targets of Dryk1B include FOXO1, SIRT1/2, HIF1a, and glycogen synthase all of which are involved in glucose homeostasis [39] . Dyrk1A promotes food intake via direct phosphorylation and activation of SIRT1, which in return deacytylates and activates FOXO. FOXO increases the expression of NPY thus promoting food intake [40] . Moreover, Dryk1A and 1B are highly expressed in the arcuate nucleus, olfactory bulb, and hippocampus. This suggests that Dyrk1B may play an important role in appetite regulation. NPY is also postulated to increase Dyrk1B expression via the PKA-CREB pathway, as Dyrk1B has a CREB motif in its promoter region [41] .
In addition, Dyrk1B has been shown to influence cell cycle activity by increasing the turnover of p27 kip (CDKN1B) [42] . Interestingly, mice deficient in p27 develop atherosclerosis, obesity, and insulin resistance, whereas those overexpressing p27 are protected against atherosclerosis [43] .
CONCLUSION
With the advent of modern molecular genetics, different approaches have been used to identify the genetic causes of MetS. Most progress has been made in identification of common variants that increase the risk for one or two metabolic risk factors. Study of larger and more homogenous populations is necessary to identify variants that underlie the association of the diverse metabolic traits of this syndrome. Genetic studies of outlier kindreds with extreme forms of MetS have led to identification of variants with large effects. The advantage of this approach is the effect size of the variants and the potential in characterizing their functional effects in vitro and in vivo. Many of these variants such as Dyrk1B are potential targets for development of novel drugs against this syndrome.
